{rfName}
Ef

Indexed in

License and use

Citations

49

Altmetrics

Analysis of institutional authors

Gimeno Mallench, LuciaAuthor

Share

June 21, 2024
Publications
>
Article
No

Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults

Publicated to:International Journal Of Clinical Pharmacology And Therapeutics. 53 (5): 377-390 - 2015-05-01 53(5), DOI: 10.5414/CP202171

Authors: Borras-Blasco, Joaquin; Castera, Dolores-Elvira; Cortes, Xavier; Javier Abad, F; Dolores Rosique-Robles, J; Gimeno Mallench, Lucia

Affiliations

Hosp Sagunto, Dept Internal Med, Valencia 46520, Spain - Author
Hosp Sagunto, Dept Pharm, Valencia 46520, Spain - Author

Abstract

Aim: To discuss the available data regarding the off-label uses of anti-TNF agents in non-infectious uveitis. Data source: A literature search was performed in Medline through PubMed from January 2001 to January 2014. Study selection and data extraction: English-language articles about uveitis treatment with anti-TNF drugs in adult patients were reviewed. Data synthesis: The use of anti-TNF-alpha drugs for treatment of several refractory manifestations of refractory uveitis in adult patients is increasing. However, due to the lack of evidence from randomized controlled trials, the use of anti-TNF in uveitis remains "off-label" in most countries. There is no trial-based evidence to support it except for the experience provided by cases and case series. This experience, which is continuously increasing, has yielded encouraging results. Anti-TNF-alpha drugs, such as infliximab, adalimumab, and golimumab, are reasonably effective for controlling ocular inflammation and sparing patients corticosteroid treatment in non-infectious refractory uveitis. Approximately 80% of patients on infliximab, adalimumab, or golimumab were able to achieve sustained control of inflammation by 6 months. Conclusion: Anti-TNF-alpha therapy is effective in inducing clinical remission for refractory uveitis, with a relatively low rate of treatment-ending adverse events. However, randomized and controlled trials are required to adequately assess the maintained clinical efficacy and safety profile in the long term of anti-TNF agents for non-infectious refractory uveitis.

Keywords

AdalimumabAdamantiades-behcet-diseaseAntibodies, monoclonalAntibodies, monoclonal, humanizedAntitumor necrosis factorFollow-upGolimumaGolimumabHumansImmunosuppressive agentsInfliximabJuvenile idiopathic arthritisLong-term treatmentOcular inflammationPosterior uveitisProspective triaRemission inductionSight threatening uveitisTnfTnf-alpha therapyTreatment outcomeTumor necrosis factor-alphaUveitis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal Of Clinical Pharmacology And Therapeutics, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Pharmacology & Pharmacy, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.53, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 15
  • Europe PMC: 13

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 68 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (GIMENO MALLENCH, LUCIA).